NuCana plc
NCNA · Pharmaceutical Preparations · EDGAR filings ↗
Grade
C56gen composite 29pct→56
Notable findings
- No interest coverageInterest coverage -1.59 (cannot cover interest)
- Cash burnNegative free cash flow (-10.0M)
- Notable holderHeld by 1 notable fund(s): CITADEL ADVISORS LLC (as of 2026-03-31)
- Trial readout soonUpcoming trial readout ~2026-08 — PHASE1/PHASE2 · Advanced Cancer
Key metrics
Return on equity
-120.7%
Return on assets
-98.4%
ROIC
-65.3%
Interest coverage
-1.6×
Current ratio
5.6×
Free cash flow
-$10M
Tangible book value
$30M
Cash & investments
$33M
Cash runway
13q
Leadership & compensation
| Name | Role | Latest total comp |
|---|---|---|
| Bloss Jeffrey D. | Chief Medical Officer | — |
| Bruce Theresa Margaret Ms | Chief Operating Officer | — |
| Levy Elliott M. | Director | — |
Officers & directors from SEC filings (Form 4 + DEF 14A proxy); compensation is the latest reported fiscal year.
Clinical trials
| Trial | Title | Phase | Status | Primary completion |
|---|---|---|---|---|
| NCT03829254 ↗ | A Safety, Pharmacokinetic and Clinical Activity Study of NUC-7738 in Patients With Advanced Solid Tumours and Lymphoma Advanced Cancer, Lymphoma | PHASE1/PHASE2 | Recruiting | 2026-08-01 |
| NCT05714553 ↗ | NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours Advanced Cancer, Advanced Solid Tumor | PHASE1/PHASE2 | Terminated | 2025-05-30 |
| NCT05678257 ↗ | A Study of NUC-3373 in Combination With Other Agents in Patients With Colorectal Cancer Colorectal Cancer, Colorectal Neoplasms | PHASE2 | Terminated | 2024-08-29 |
| NCT03428958 ↗ | A Safety, Pharmacokinetic and Efficacy Study of NUC-3373 in Combination With Standard Agents Used in Colorectal Cancer Treatment Colorectal Cancer, Colorectal Neoplasms | PHASE1/PHASE2 | Completed | 2024-03-19 |
| NCT04163900 ↗ | Comparing NUC-1031 Plus Cisplatin to Gemcitabine Plus Cisplatin in Patients With Advanced Biliary Tract Cancer Biliary Tract Cancer | PHASE3 | Terminated | 2022-03-02 |
| NCT03146663 ↗ | NUC-1031 in Patients With Platinum-Resistant Ovarian Cancer Ovarian Cancer | PHASE2 | Terminated | 2019-12-31 |
| NCT01621854 ↗ | NUC-1031 in Patients With Advanced Solid Tumours Cancer | PHASE1 | Completed | 2015-06-01 |
Source: ClinicalTrials.gov (U.S. NIH) · active studies first.
Recent filings
| Form | Filed | Period | Accession |
|---|---|---|---|
| 20-F | 2026-03-19 | 2025-12-31 | 0001193125-26-116030 ↗ |
| 20-F | 2025-03-20 | 2024-12-31 | 0000950170-25-042709 ↗ |
| 20-F | 2024-03-20 | 2023-12-31 | 0000950170-24-034208 ↗ |
| 20-F | 2023-04-04 | 2022-12-31 | 0000950170-23-011778 ↗ |
| 20-F | 2022-04-27 | 2021-12-31 | 0001564590-22-016088 ↗ |
| 20-F | 2021-03-04 | 2020-12-31 | 0001564590-21-010959 ↗ |
| 20-F | 2020-03-10 | 2019-12-31 | 0001564590-20-009788 ↗ |
| 20-F | 2019-03-07 | 2018-12-31 | 0001564590-19-006811 ↗ |
| 20-F | 2018-03-22 | 2017-12-31 | 0001564590-18-006509 ↗ |